Compare Ascendis Pharma A/S (ASND) vs Nvidia Corp (NVDA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Nvidia Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Nvidia Corp trades at $208.48 (market cap $5.11T). The key difference: Nvidia Corp is far larger — about 288× Ascendis Pharma A/S's market cap, and Nvidia Corp pays a 0.47% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NVDA | |
|---|---|---|
Market Cap | $17.74B | $5.11T |
Sector | Health | Technology |
52-Week High | $277.18 | $235.75 |
52-Week Low | $163.32 | $164.07 |
Enterprise Value | $18.11B | $5.04T |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
NVIDIA (NVDA) trades at $210.96, up 4.07% in the last session, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.87 exceeding the $1.76 estimate. Revenue surged to $130.50 billion in 2025, driving a net income margin of 62.97%. Analyst consensus is strongly bullish, with a price target of $324.95.
The outlook remains positive due to NVIDIA's AI chip dominance and accelerating revenue growth, though risks include peak AI spending concerns and increased competition. The stock offers significant upside to the consensus target, but investors should weigh valuation multiples against execution risks in a dynamic market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
